Market Overview

Cincinnati Nurse Debuts CBD Product Line

Share:

At the moment, interest in hemp-derived cannabidiol (CBD) is at an all-time high. Ever since the 2018 Farm Bill legalized hemp and by extension CBD, the market for products infused with CBD has been steadily rising. Experts estimate that the industry will be worth at least $20 billion by 2026. However, the sector has been […]

At the moment, interest in hemp-derived cannabidiol (CBD) is at an all-time high. Ever since the 2018 Farm Bill legalized hemp and by extension CBD, the market for products infused with CBD has been steadily rising. Experts estimate that the industry will be worth at least $20 billion by 2026.

However, the sector has been plagued by one issue: quality control. As many have put it, the hemp/CBD industry rapidly outpaced regulatory authorities, resulting in a market filled with substandard and contaminated products.

A nurse is Cincinnati is looking to change that. Jeri Schulz, a registered nurse, launched her company online, and it will sell a variety of high-quality hemp-based CBD products. Dubbed ‘Tulip Tree', the West Chester-based company will sell tinctures, gummies and pet treats. According to Schulz, it will focus on providing prescription-free alternatives for health and wellness.

Pharmaceuticals are notorious for their side effects, some of them quite extreme. CBD, on the other hand, doesn't have side effects, although high amounts of CBD have been found to affect the liver. Although there's little scientific research to back the claims, users have said CBD offers relief from a variety of ailments including chronic pain and anxiety.

Epidiolex, a CBD-based drug, is the only instance a medical claim has been properly researched and validated. The U.S. Food and Drug Administration (FDA) approved the drug to treat two rare pediatric epilepsies, Lennox-Gastaut Syndrome and Dravet Syndrome.

Schulz is working with a Colorado-based CBD supplier and a Florida packaging firm. She has experience in hospice, critical care, cardiology, and natural medicine, and she says that she envisions Tulip Tree as a resource for nurses and other health care professionals interested in self-care. She also wants guidance for patients on the safe and effective use of CBD products, custom dosing, and understanding potential drug interactions.

"I want to market to the health care community. The nursing profession is a mentally, emotionally and physically demanding job. These people have a passion for this, but nurses are burning out because it's such a stressful job."

Prices for their products start at $14.95 for CBD gummies, and the high-end stuff costs $65.95. The company also has some products for pets. The Fur Baby Balance Premium Pet Phytos Dog Chews costs $35.95 for 30 beef-flavored chews with 2 mg of CBD.

The company extracts all of the THC (delta-9 tetrahydrocannabinol) from the hemp during processing. All the finished products go through third-party lab testing to make sure they are devoid of solvents, heavy metals, and pesticides.

"I think my products stand out. There are only a handful of companies out there that have premium products. It's a little more expensive as a product because of the extra filtration to remove the THC. It was important to me because my marketing is going to nursing and health care professionals. They don't want anything that might have THC in it because they were afraid of being tested THC positive," she says.

CBD sector players like The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (OTCQX:TGODF) and IONIC Brands Corp. (CSE:IONC) (OTC:IONKF) could be happy that medical professionals like Shulz are joining the cannabidiol industry since this will help to avail more trustworthy sources of information about CBD.

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com